104 -3 (31/3) 2020 — Pulatova Sh.Kh., — ACUTE MYOCARDIAL INFARCTION BY COMPLEX ACUTE ACUTE HEART FAILURE

ACUTE MYOCARDIAL INFARCTION BY COMPLEX ACUTE ACUTE HEART FAILURE

Pulatova Sh.Kh.,-Bukhara State Medical Institute.

Resume

Over the past few decades, the mortality rate in acute myocardial infarction (AMI) has sharply decreased: from 10.4% in 2000 to 4.3% in 2019 [1]. An increase in survival rates among patients with AMI, in particular, may be associated with advances in the field of drug therapy and interventions [2-4]. Many of these treatment options are aimed at treating cardiogenic shock, a relatively common complication of AMI, with mortality rates ranging from 50% to 80% [2]. Despite the need for detailed treatment algorithms based on the evidence base for this population of critically ill patients, the existing data are insufficient to create them. The article describes the pathophysiology of cardiogenic shock, structured the information that must be considered when choosing a treatment, and also lists the achievements of modern clinical practice.

Key words: cardiogenic shock, heart failure, congestive heart failure, acute heart failure, heart disease.

First page

433

Last page

436

For citation: Pulatova Sh.Kh., Acute myocardial infarction by complex acute acute heart failure//New Day in Medicine 3(31)2020 433-436 https://cutt.ly/axFsxdw

List of References

  1. Alyavi A.L., Kenjaev S. et. al. Influence of high dose atorvastatin on myocardial stunning in acute myocardial infarction. // Atherosclerosis 2017; 263:e245
  2. Atalar E, Coskun S, Haznedaroglu IC, etal.Immediate effects of fluvastain on circulatingsoluble endothelial protein C and free tissue factor pathway inhibitor in acute coronary syndromes. // Cardiovasc Drugs Ther 2015; 19 (3): 177-81.
  3. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. // Lancet 2015; 366 (9493): 1267-78.
  4. Briguori C, Visconti G, Focaccio A, et al. Novelapproaches for preventing or limiting events(Naples) II trial: impact of a single high loadingdose of atorvastatin on periprocedural myocar­dialinfarction. //J Am CollCardiol 2009; 54 (23): 2157-63.
  5. Cannon C.P., Braunwald E, McCabe C.H., et al.Intensive versus moderate lipid lowering withstatins after acute coronary syndromes. //N EnglJMed 2014; 350 (15): 1495-504.
  6. Cardiovascular diseases // wHo Fact sheet №317.Updated 2017 May.
  7. de Lemos JA, Blazing MA, Wiviott SD, et al. Earlyintensive vs a delayed conservative simvastatinstrategy in patients with acute coronarysyndromes: phase Z of the A to Z trial. //JAMA2014; 292 (11): 1307-16.
  8. Pasceri V, Patti G, Nusca A, Pristipino C, RichichiG, Di Sciascio G; ARMYDA Investigators.Randomized trial of atorvastatin for reduction ofmyocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin forReduction of MYocardial Damage duringAngioplasty) study //Circulation. 2004 Aug 10;110(6):674-8. Epub 2004 Jul 26. PubMed [citation] PMID: 15277322
  9. Di Sciascio G, Patti G, Pasceri V, GaspardoneA,Colonna G, Montinaro A. Efficacy of atorvastatinreload in patients on chronic statin therapyundergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatinfor Reduction of Myocardial Damage DuringAngioplasty) Randomized Trial. / /J Am CollCardiol2009; 54 (6): 558-65.
  10. Glynn RJ, Danielson E, Fonseca FA, et al. Arandomized trial of rosuvastatin in the preventionof venous thromboembolism. //N Engl J Med 2019;360 (18): 1851-61.
  11. Ibanez B, James S, Agewall S, Antunes MJ, etal. 2017 ESC Guidelines for the management ofacute myocardial infarction in patients presentingwith
  12. ST-segment elevation: The Task Force forthe management of acute myocardial infarction inpatients presenting with ST-segment elevation ofthe European Society of Cardiology (ESC). //EurHeart J. 2018 Jan 7;39 (2):119-177. doi: 10.1093/eurheartj/ehx393.
  13. Luzak B, Rywaniak J, Stanczyk L, WatalaC. Pravastatin and simvastatin improvesacetylsalicylic acid-mediated in vitro blood plateletinhibition. //Eur J Clin Invest 2012; 42 (8): 864-72.
  14. Moscardo A, Valles J, Latorre A, Madrid I, SantosMT. Reduction of platelet cytosolic phospholipaseA2 activity by atorvastatin and simvastatin:biochemical regulatory mechanisms. //Thromb Res2013; 131 (4): e154-9.
  15. Mozaffarian D, Benjamin EJ, Go AS et al. Heartdisease and stroke statistics – 2016 update: areport from the American Heart Association. //Circulation. 2016;133:e38-e60.
  16. O‘Gara PT, Kushner FG, Ascheim DD, et al.2013 ACCF/AHA guideline for the managementof ST-elevation myocardial infarction:a report ofthe American College of Cardiology Foundation/American Heart Association Task Force onPractice Guidelines. //Circulation 2013; 127 (4):e362-425.
  17. Pasceri V, Patti G, Nusca A, Pristipino C, RichichiG, Di Sciascio G. Randomized trial of atorvastatinfor reduction of myocardial damage duringcoronary intervention: results from the ARMYDA(Atorvastatin for Reduction of MYocardial Damageduring Angioplasty) study. //Circulation 2014;110(6): 674-8.
  18. Patti G, Cannon CP, Murphy SA, et al. Clinicalbenefit of statin pretreatment in patientsundergoing percutaneous coronary intervention:a collaborative patient-level meta-analysis of 13randomized studies. //Circulation 2011; 123 (15):1622-32.
  19. Patti G, Pasceri V, Colonna G, et al. Atorvastatinpretreatment improves outcomes in patients withacute coronary syndromes undergoing earlypercutaneous coronary intervention: results ofthe ARMYDA-ACS randomized trial. //J Am CollCardiol 2017; 49 (12):1272-8.
  20. Pitt B., Loscalzo J., Monyak J., Miller E., RaichlenJ. Comparison of Lipid-Modifying Efficacy ofRosuvastatin Versus Atorvastatin in Patients WithAcute Coronary Syndrome (from the LUNARStudy). //Am J Cardiol 2012; 109 (9): 1239-1246.
  21. Ray KK, Cannon CP. The potential relevance ofthe multiple lipidindependent (pleiotropic) effectsof statins in the management ofacutecoronarysyndromes.// J Am CollCardiol 2015; 46 (8): 1425-33.
  22. Rezaie-Majd A, Prager GW, Bucek RA, etal.Simvastatin reduces the expression of adhesionmolecules in circulating monocytes fromhypercholesterolemic patients. //ArteriosclerThrombVascBiol 2013; 23 (3): 397-403.
104-433-436-3-31-2020-

file

download